lcSSc
…ine in lcSSc. In addition, a trial of tofacitinib with 40 (61%) lcSSc patients showed that this drug was more effective than low-dose…
7articles mentioning diseases
62disease mentions
1distinct diseases extracted
0%of mentions human-reviewed
Active filtersEntity: lcSSc ×
lcSSc
This disease is selected. Its supporting articles are shown below.
Articles mentioning lcSSc
7 articles · page 1 of 1sine sclerodermalcSScLimited cutaneous Systemic sclerosisCONQUERantiTOPOenteral/parenteral nutrition
…f patients with early SSc, 5% and 11% of patients with lcSSc or sine scleroderma experienced disease progression at 12 and 24 months, respective…
lcSScdcSScscleroderma renal crisispulmonary arterial hypertensiondiffuse cutaneous systemic sclerosisPAH
… (HR 0.49; 95% CI:0.36-0.67, p<0.001) (figure 2).Conclusions In lcSSc, clinically meaningful progression, defined by MINIMISE endpoin…
lcSScinterstitial lung diseasediffuse cutaneous systemic sclerosismyositismyocarditisarthritisSSclimited cutaneous systemic sclerosismycophenolate mofetil
…%). Interestingly, a majority of respondents would likely treat lcSSc in the presence of subclinical organ involvement, including sub…
sine sclerodermalcSScSScLimited cutaneous systemic sclerosis
…he EUSTAR database. Patients were included if they had lcSSc or sine scleroderma, fulfilled the 2013 ACR/EULAR classification criteria, and had …
systemic sclerosis (SSc)interstitial lung diseaseinterstitial lung disease (ILD)cutaneous fibrosislcSScILDIcSScMycophenolate MofetilMMFiloprost+3 more
…y treatment for interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and is an option for cutaneous fibrosis. However, its use in pa…